Sight Sciences, Inc. 8K

Sight Sciences reported strong Q1 2026 revenue growth and margins, benefited from a favorable patent litigation judgment against Alcon, and raised full-year 2026 revenue guidance while reaffirming expense guidance despite ongoing net losses.

Sight Sciences, Inc. reported first quarter 2026 results showing a return to double-digit year-over-year revenue growth to $19.7 million, strong gross margins of 86%, reduced cash usage, and significant expansion in its Interventional Dry Eye segment, while maintaining modest growth in Interventional Glaucoma; the company also highlighted a favorable final judgment in its patent infringement case against Alcon that preserved a $55.4 million damages award and a 10% ongoing royalty (subject to appeal), raised its full-year 2026 revenue guidance to $83–89 million, and reaffirmed its adjusted operating expense guidance of $93–96 million despite continuing to report a net loss.

Filing Facts

CIK

1531177

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-208959

Alert Tier

7